Results 71 to 80 of about 558,869 (280)
Host directed therapies: COVID-19 and beyond
Current Research in Pharmacology and Drug Discovery, 2021 The global spread of SARS-CoV-2 has necessitated the development of novel, safe and effective therapeutic agents against this virus to stop the pandemic, however the development of novel antivirals may take years, hence, the best alternative available, is to repurpose the existing antiviral drugs with known safety profile in humans. After more than one
Devavrat Tripathi +3 more
openaire +3 more sources
Targeting immunometabolism in host-directed therapies to fungal disease [PDF]
Clinical and Experimental Immunology, 2021 Summary Fungal infections affect over a billion people and are responsible for more than 1.5 million deaths each year. Despite progress in diagnostic and therapeutic approaches, the management of severe fungal infections remains a challenge.
Gonçalves, Samuel M +3 more
openaire +2 more sources
Uncovering the transcriptional control of "Bartonella henselae" host adaptation factors [PDF]
, 2014 A recurrent theme in bacterial pathogenicity is the understanding of the regulatory events necessary for a given pathogen to progress through its infection cycle while resisting the host defense mechanisms.
Québatte, Maxime
core +1 more source
Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review [PDF]
, 2017 © 2015 The Author(s) Infection by the intracellular bacterial pathogen Mycobacterium tuberculosis (Mtb) is a major cause of morbidity and mortality worldwide.
Chambers, M +3 more
core +2 more sources
International Journal for Parasitology: Drugs and Drug Resistance, 2019 Visceral leishmaniasis (VL) is associated with treatment complications due to the continued growth of resistant parasites toward currently available pathogen-directed therapeutics.
M. Shamim Hasan Zahid +6 more
doaj +1 more source
Bazedoxifene Suppresses Intracellular
mSphere, 2020 Tuberculosis (TB) is still the leading killer caused by Mycobacterium tuberculosis infection. There is a clear need for new treatment strategy against TB.
Qi Ouyang +5 more
doaj +1 more source
Can We Harness Immune Responses to Improve Drug Treatment in Leishmaniasis?
Microorganisms, 2020 Leishmaniasis is a vector-borne parasitic disease that has been neglected in priority for control and eradication of malaria, tuberculosis, and HIV/AIDS.
Raphael Taiwo Aruleba +3 more
doaj +1 more source
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches
Trends in Pharmacological Sciences, 2022 Host-directed therapies (HDTs) that modulate host-pathogen interactions offer an innovative strategy to combat Mycobacterium tuberculosis (Mtb) infections. When combined with tuberculosis (TB) antibiotics, HDTs could contribute to improving treatment outcomes, reducing treatment duration, and preventing resistance development.
Mehta, K.M. +4 more
openaire +4 more sources
Metformin Increases Cell Viability and Regulates Pro-Inflammatory Response to Mtb
Infection and Drug Resistance, 2023 Nikita Naicker,1 Hylton Rodel,2 Rubeshan Perumal,1 Yashica Ganga,2 Mallory Bernstein,2 Ntombi Benede,2 Salim Abdool Karim,1,3 Nesri Padayacthi,1,3 Alex Sigal,2,4,5 Kogieleum Naidoo1,3 1Centre for the AIDS Programme of Research in South Africa (CAPRISA ...
Naicker N +9 more
doaj
Reciprocal control of viral infection and phosphoinositide dynamics
FEBS Letters, EarlyView.Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley +1 more source